BeOne’s Cancer Has No Borders Podcast
Episode 11 of BeOne’s Cancer Has No Borders podcast features Pat Garcia-Gonzalez, the CEO of The Max Foundation. Watch Now
Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award
We are pleased to announce The Max Foundation CEO and co-founder, Pat Garcia-Gonzalez, has been nominated as one of three finalists for the Outstanding Contribution to Cancer Control Award, by UICC. We are honored to see The Max Foundation’s efforts recognized by the UICC.
Pat Garcia-Gonzalez shared her gratitude, saying, “This nomination means the world to me and to all whose voices we represent. At The Max Foundation we believe that all people should be able to access the treatment they need, geography should not be destiny, and everyone should be able to strive for health with dignity and hope.
In the past 20 years we have demonstrated that it is possible to safely treat many cancers in low- and middle-income countries. Now we can prevent unnecessary suffering and premature death and because we can, we must.”
Pat is nominated in the civil society category, alongside Paul Farmer, Co-Founder and Chief Strategist, Partners in Health, and Maira Caleffi, breast surgeon and founder of FEMAMA. UICC has also nominated President Joe Biden, Minister Greg Hunt, and President Paul Kagame in the policy-makers category.
The panel of judges for UICC’s Outstanding Contribution to Cancer Control Awards includes: the members of the Board of the Union for International Cancer Control (UICC); the Editors in Chief of the three following scientific journals: Lancet Oncology, International Journal of Cancer, Journal of Global Oncology; and the CEO of the American Society for Clinical Pathology.
The Awards Ceremony will take place October 26th at the 2021 World Cancer Leaders’ Summit in Boston.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
New study confirms an excellent survival rate of cancer patients in a medication donation program
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….